480 PLEASANT STREET, WATERTOWN, MA
EyePoint, Inc. Files Complaint Against Ocular Therapeutix for Defamation
Financial Results, Press Release
Investor Presentation
Reports Corporate Update and Anticipated Pivotal Milestones for 2026
EyePoint Pharmaceuticals Changes Name to EyePoint, Inc. Effective December 8,...
Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
EyePoint Pharmaceuticals Files $200 Million Common Stock Prospectus Supplement
Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Free Writing Prospectus
Submission Upload